Actinic Keratosis News and Research

RSS
Actinic keratosis, also known as solar keratosis, is a dry, scaly patch of skin that presents as a result of chronic exposure to sunlight. Most people with the condition do not report significant symptoms, although the condition can progress to a type of skin cancer, squamous cell carcinoma, in severe cases without treatment.
PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

PhotoMedex terminates exclusive distribution agreement between Radiancy and Ya-Man in Japan

PhotoMedex terminates exclusive distribution agreement between Radiancy and Ya-Man in Japan

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

New study highlights that physicians prefer topical therapies for actinic keratosis

New study highlights that physicians prefer topical therapies for actinic keratosis

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

UT professor earns INNOVATOR Award for Cancer Prevention Research at AACR meeting 2013

UT professor earns INNOVATOR Award for Cancer Prevention Research at AACR meeting 2013

EC grants marketing authorization to Meda's Zyclara for treatment of actinic keratosis

EC grants marketing authorization to Meda's Zyclara for treatment of actinic keratosis

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

German BfArM grants Moberg Derma approval to initiate Limtop phase II actinic keratosis trial

German BfArM grants Moberg Derma approval to initiate Limtop phase II actinic keratosis trial

New topical gel decreases amount of time needed to treat actinic keratosis

New topical gel decreases amount of time needed to treat actinic keratosis

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

PhotoMedex fourth quarter revenues increase 26% to $28.8M

PhotoMedex fourth quarter revenues increase 26% to $28.8M

LEO Pharma receives FDA approval for Picato topical gel to treat AK

LEO Pharma receives FDA approval for Picato topical gel to treat AK

Scientists decode unknown mechanism of imiquimod in tumour defense

Scientists decode unknown mechanism of imiquimod in tumour defense

Moberg Derma receives Vinnova grant to develop Limtop for actinic keratosis, genital warts

Moberg Derma receives Vinnova grant to develop Limtop for actinic keratosis, genital warts

Beta HPV prophylactic strategies may have a positive impact on prevention of NMSC

Beta HPV prophylactic strategies may have a positive impact on prevention of NMSC

Graceway receives FDA approval for Zyclara Cream to treat actinic keratoses

Graceway receives FDA approval for Zyclara Cream to treat actinic keratoses

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.